Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CII-synNotch T cells
- Development stage
- Preclinical
- Lead developer
- University of California, San Francisco
- Modality
- Cell Therapies
- Administration
- Intraarticular
01
Overview
CII-synNotch T cells are an engineered cell therapy designed for the targeted treatment of osteoarthritis (OA). These T cells express a synthetic Notch (synNotch) receptor featuring an extracellular recognition domain (ERD) derived from a monoclonal antibody (mAbCII) that specifically recognizes type II collagen (CII) epitopes exposed only in degraded articular cartilage. Upon binding to CII, the synNotch receptor undergoes proteolytic cleavage, releasing a synthetic transcription factor (intracellular domain) that translocates to the nucleus to drive the expression of therapeutic payloads. This system allows for spatially constrained, disease-specific transgene production, potentially reducing off-target effects compared to constitutive expression. The platform has been optimized using a single-chain fragment antigen-binding (scFab) architecture to enhance activation in T cells.
- Other names
- CII-synNotch Jurkat cellscollagen-specific synNotch T cells
02
Targets
COL2A1
Beyond the preview
Go deeper on CII-synNotch T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CII-synNotch T cells.